MW
Megen Wittling
US Food and Drug Administration, Emory University, Georgia Institute of Technology
0000-0002-3631-4955
Employment
-
US Food and Drug Administration ORISE Research Fellow2018 - 2019
Education
-
Emory University MD/PhD Candidate2019 - Present
-
Georgia Institute of Technology Bachelor of Science in Biology2014 - 2018
Projects & Funding
Projects & funding information is unavailable.
Publications (28)
- Data from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Table 2 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Table 1 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Figure 9 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Figure 8 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Figure 7 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Figure 6 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Figure 4 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save
- Supplemental Figure 3 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy Save